Investor Relations

SEC Filings

  o View CEL-SCI's SEC Filings  
       
  o View CEL-SCI's Section 16 Filings  

Stock Quotes

  o NYSE AMEX  

Corporate Presentation

  o View CEL-SCI Presentation  

Press Releases

  o Press Releases  
  NOVEMBER 1, 2010
12:22 PM NEW STORY CEL-SCI Corporation Receives $733,437 Grant under the Patient Protection and Affordable Care Program
  OCTOBER 20, 2010
09:15 AM NEW STORY CEL-SCI Corporation Receives Approval from Seven Hospital Institutional Review Boards in India to Commence Phase III Clinical Trial of Multikine in Head and Neck Cancer
  OCTOBER 12, 2010
09:35 AM NEW STORY CEL-SCI Corporation Receives Approval from First Taiwanese Institutional Review Board to Commence Phase III Clinical Trial of Multikine in Head and Neck Cancer
  OCTOBER 5, 2010
09:00 AM CEL-SCI Corporation Receives Approval from Hungary to Commence Phase III Clinical Trial of Multikine in Head and Neck Cancer
  SEPTEMBER 27, 2010
09:00 AM CEL-SCI Corporation Receives Russian Federation Ethical Council Approval for Multikine Phase III Clinical Trial in Head and Neck Cancer
  SEPTEMBER 13, 2010
09:45 AM CEL-SCI Corporation Receives Approval from North Mississippi Health Services' Institutional Review Board to Commence Phase III Clinical Trial of Multikine in Head and Neck Cancer


Read the latest Letter to Shareholders 

  o Letter to Shareholders  

Read the latest Research Report on CEL-SCI

  o Research Report  

Investor Relations Contact

   

Gavin de Windt
Phone: +1 703-506-9460
E-mail: gdewindt@cel-sci.com

 

 

Research &
Clinical Trials

 

  

SEC Filings